



Liontrust UK Micro Cap Fund

September 2022 review

Fund managers: Matthew Tonge, Anthony Cross, Julian Fosh, Victoria Stevens and Alex Wedge

The Liontrust UK Micro Cap Fund returned -6.6%* in September. The FTSE Small Cap (excluding investment trusts) Index and the FTSE AIM All-Share Index comparator benchmarks both returned -8.5%. The average return of funds in the IA UK Smaller Companies sector, also a comparator benchmark, was -9.1%.

A higher-than-expected US inflation reading (8.3% year-on-year for August) removed any small possibility that inflation would drop out of investors' key concerns during September. The US Federal Reserve reacted by raising rates a further 75 basis points – its third consecutive hike of this size – and commenting that further economic pain was likely as more tightening is implemented

Equity markets softened and government bond yields rose, trends which were accentuated in the UK towards the end of the month by an adverse market reaction to UK Chancellor Kwasi Kwarteng's 'mini-budget'. Having already committed support worth an estimated £150bn to cap household energy bills, the Chancellor went on to announce a package of fiscal stimulus which included around £45bn of tax cuts. Additional borrowing of £72bn will be needed this year to support the plans; markets signalled strongly that they viewed the measures as damaging to the UK's credit quality. In trade-weighted terms, the pound lost almost 5% to its low on 26th September. UK Government bonds sold off extremely sharply, with, for example, the 5 year bond hitting a high of 4.7% on 27th, up nearly 200 percentage points on the month and up by around 110 points since the budget announcement a couple of days earlier. At this point, the Bank of England moved to stabilise markets – temporarily reinstating its bond-buying quantitative easing efforts – over fears of potential systemic solvency issues for some pension funds.

On the UK equity market, these events only served to deepen the year's existing trend of weakness concentrated in mid and small caps. While the large-cap FTSE 100 monthly return of -5.2% was bad enough, the mid-cap FTSE 250 returned -9.7% and the FTSE Small Cap registered -8.5%.

Earlier in the year, share weakness in these areas seemed to stem predominantly from ratings contracting – i.e. the 'p' in p/e levels falling – as investors priced in higher interest rates (and discount rates) on future expected growth. More recently, as recessionary forces have built, earnings estimates have come under pressure, prompting further share price weakness.

It is understandable that the market might be concerned that mid and small-caps in aggregate would be disproportionately affected by the problems faced by the UK's domestic economy. While we by no means claim that any of our companies will be immune from a contraction in the UK economy, we have so far been reassured by the trading resilience shown by many of them. Over time, we would expect their high-quality characteristics to allow them to outperform the average company, especially against a tough economic backdrop.

Resilient performers include **Surgical Innovations Group** (+13%), which moved higher after interim results included upbeat commentary on recent trading. The maker of medical technology for minimally invasive surgery said that UK revenues exceeded management expectations, almost regaining pre-pandemic levels in most markets. Overall, group revenues for July and August were around 113% above the level seen last year.

Other holdings to defy the widespread market weakness this month included **Quixant** (+11%), after well-received interim results and news of a mass production order for gaming cabinets, and **Churchill China** (+5.2%), which delivered a reassuring set of interims results showing 73% revenue growth and record order book levels

However, global supply chain bottlenecks remain an issue and contributed to the falls experienced by two portfolio holdings in September. A trading update from **Oxford Metrics** (-20%) stated that although it continues to experience high demand, supply chain issues have forced it to defer around £3.5m of shipments to next financial year. As a result, it now thinks it will fall short of market expectations for the year to 30 September 2022. In a similar story, an AGM update from **Adept Technology** (-20%) struck an upbeat tone on new business wins and contract extensions but warned that project delivery is being delayed by global semiconductor shortages.

Frontline healthcare services provider **Totally** (-23%) has experienced high demand since the pandemic began, but its shares sold off heavily in September as it issued a short AGM statement noting that it faces the same operating pressures as the NHS when it comes to staffing, recruitment and cost inflation.

The drop at **Keystone Law** (-25%) seemed more reflective of a very tough market environment than company-specific headwinds. The platform law firm released interim results for the period to 31 July it commented that it was on track to deliver a full-year outcome “comfortably in line” with expectations.

Inevitably, markets use a very broad brush when reacting to economic developments and do not differentiate between different companies until later in the cycle when the successful ones are able to show, by their delivered results, their superiority. We believe that our funds are invested in dependable, consistent businesses in possession of barriers to competition which gives them pricing power. This pricing power is likely to prove critical in dealing with cost pressures that look set to persist for some time.

Because our investment process focuses on intangible asset strengths, it has a bias towards less (physical) asset-intensive businesses. Our smaller companies also often have a strong owner-manager culture, a consequence of a requirement for at least 3% senior management equity ownership. This tends to be accompanied by a more conservative business ethos focused on organic growth and lower balance sheet gearing. Almost 80% of the Fund’s companies are in a position of net cash. While heavily indebted, capital-intensive companies are exposed to rising interest costs and inflated capex spending, our businesses should be able to prioritise capital allocation towards growth and investment. Hopefully, this should set them up to emerge from the current macroeconomic turmoil in decent shape and thrive once conditions normalise.

In the meantime, we have been trying to view the UK market sell-off as a period of disruption which should present investment opportunities, particularly lower down the size scale. We have been looking for opportunities to initiate or top-up positions in high quality, strong businesses with Economic Advantage characteristics at materially cheaper levels than we were able to at the start of the year.

As we have previously observed, market weakness may also lead to more interest from corporate acquirers. During September, **Attraqt Group** (+55%) was the latest holding to receive a takeover approach. Its board recommended a 30p per share offer from a group led by K1 Investment Management, a private equity business which targets enterprise software. The bid level is a 50%+ premium to Attraqt’s prior share price, but only takes it back to levels it traded at in May – before it warned that sales lead times were lengthening as its consumer-facing clients suffered from current economic conditions.

Positive contributors included:

Attraqt Group (+55%), Cerillion (+14%), Surgical Innovations Group (+13%), Quixant (+11%) and Churchill China (+5.2%).

Negative contributors included:

Keystone Law Group (-25%), Totally (-23%), Oxford Metrics (-20%), Adept Technology (-20%) and Arbuthnot Banking Group.

Discrete years' performance (%), to previous quarter-end:**

Past performance does not predict future returns

	Sep-22	Sep-21	Sep-20	Sep-19	Sep-18
Liontrust UK Micro Cap I Acc	-26.6%	63.2%	10.6%	-2.5%	24.0%
FTSE Small Cap ex ITs	-24.4%	72.4%	-12.7%	-7.8%	0.6%
IA UK Smaller Companies	-31.9%	51.1%	-0.4%	-7.1%	10.8%
Quartile	1	1	1	1	1

*Source: Financial Express, as at 30.09.22, total return (net of fees and income reinvested), bid-to-bid, institutional class.

**Source: Financial Express, as at 30.09.22, total return (net of fees and income reinvested), bid-to-bid, institutional class.

For a comprehensive list of common financial words and terms, see our glossary at:

<https://www.liontrust.co.uk/glossary>.

Key Risks:

Past performance is not a guide to future performance. The value of an investment and the income generated from it can fall as well as rise and is not guaranteed. You may get back less than you originally invested.

The issue of units/shares in Liontrust Funds may be subject to an initial charge, which will have an impact on the realisable value of the investment, particularly in the short term. Investments should always be considered as long term.

The portfolio is primarily invested in smaller companies and companies traded on the Alternative Investment Market. These stocks may be less liquid and the price swings greater than those in, for example, larger companies.

Disclaimer

This document is issued by Liontrust Fund Partners LLP (2 Savoy Court, London WC2R 0EZ), authorised and regulated in the UK by the Financial Conduct Authority (FRN 518165) to undertake regulated investment business. **This is a marketing communication.** It should not be construed as advice for investment in any product or security mentioned, an offer to buy or sell units/shares of Funds mentioned, or a solicitation to purchase securities in any company or investment product. Examples of stocks are provided for general information only to demonstrate our investment philosophy. The investment being promoted is for units in a fund, not directly in the underlying assets. It contains information and analysis that is believed to be accurate at the time of publication but is subject to change without notice. Whilst care has been taken in compiling the content of this document, no representation or warranty, express or implied, is made by Liontrust as to its accuracy or completeness, including for external sources (which may have been used) which have not been verified. It should not be copied, forwarded, reproduced, divulged or otherwise distributed in any form whether by way of fax, email, oral or otherwise, in whole or in part without the express and prior written consent of Liontrust. Always research your own investments and if you are not a professional investor please consult a regulated financial adviser regarding the suitability of such an investment for you and your personal circumstances.

[22/713]